MEDI 7352

Drug Profile

MEDI 7352

Alternative Names: MEDI7352

Latest Information Update: 20 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Analgesics; Anti-inflammatories; Antirheumatics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Nerve growth factor modulators; Tumour necrosis factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 09 Nov 2015 Phase-I clinical trials in Pain in Sweden, United Kingdom (IV) (NCT02508155)
  • 09 Nov 2015 Phase-I clinical trials in Pain in Sweden, United Kingdom (SC) (NCT02508155)
  • 27 Jul 2015 Preclinical trials in Pain in United Kingdom (SC, IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top